Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization

[1]  A. Penman,et al.  Prevalence of Age-Related Maculopathy , 2020 .

[2]  Z. Ivics,et al.  Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. , 2018, Current opinion in genetics & development.

[3]  Mark S. Humayun,et al.  A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration , 2018, Science Translational Medicine.

[4]  Adnan Tufail,et al.  Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration , 2018, Nature Biotechnology.

[5]  Z. Izsvák,et al.  Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  D. Scherman,et al.  The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells , 2017, Molecular therapy. Nucleic acids.

[7]  Z. Izsvák,et al.  Gene Therapy with the Sleeping Beauty Transposon System. , 2017, Trends in genetics : TIG.

[8]  T. Peto,et al.  A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015 , 2017, BMJ Open.

[9]  Z. Izsvák,et al.  Wide Awake and Ready to Move: 20 Years of Non-Viral Therapeutic Genome Engineering with the Sleeping Beauty Transposon System. , 2017, Human gene therapy.

[10]  Gretchen A. Stevens,et al.  Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. , 2017, The Lancet. Global health.

[11]  S. Temple,et al.  Development of a Refined Protocol for Trans-scleral Subretinal Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes. , 2017, Journal of visualized experiments : JoVE.

[12]  D. Scherman,et al.  Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery , 2017, Molecular therapy. Nucleic acids.

[13]  C. Sorenson,et al.  PEDF expression affects retinal endothelial cell proangiogenic properties through alterations in cell adhesive mechanisms. , 2017, American journal of physiology. Cell physiology.

[14]  T. Ciulla,et al.  Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration , 2017, Expert opinion on emerging drugs.

[15]  Z. Izsvák,et al.  Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side , 2017, Critical reviews in biochemistry and molecular biology.

[16]  D. Scherman,et al.  Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids , 2017, Molecular therapy. Nucleic acids.

[17]  L. Zechiedrich,et al.  Advances in Non-Viral DNA Vectors for Gene Therapy , 2017, Genes.

[18]  Z. Izsvák,et al.  Sleeping Beauty transposition: from biology to applications , 2017, Critical reviews in biochemistry and molecular biology.

[19]  T. Shiina,et al.  Successful Transplantation of Retinal Pigment Epithelial Cells from MHC Homozygote iPSCs in MHC-Matched Models , 2016, Stem cell reports.

[20]  Mark S. Humayun,et al.  Subretinal implantation of a monolayer of human embryonic stem cell-derived retinal pigment epithelium: a feasibility and safety study in Yucatán minipigs , 2016, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  Heng-yu Zhang,et al.  Comparison of peripheral iridectomy methods for posterior chamber phakic intraocular lens implantation in patients with brown irides , 2016, BMC Ophthalmology.

[22]  D. Clegg,et al.  An Innovative Surgical Technique for Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelium in Yucatan Mini Pigs: Preliminary Results. , 2016, Ophthalmic surgery, lasers & imaging retina.

[23]  Sofia M. Calado,et al.  pEPito-driven PEDF Expression Ameliorates Diabetic Retinopathy Hallmarks. , 2016, Human gene therapy methods.

[24]  A. García-Layana,et al.  Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. , 2016, Biochemical pharmacology.

[25]  Wei Chen,et al.  Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4+ T Cells , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Z. Izsvák,et al.  Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In Vivo , 2015, BioMed research international.

[27]  H. Uusitalo,et al.  Ultrathin Polyimide Membrane as Cell Carrier for Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelium , 2015, PloS one.

[28]  L. M. Sadaba-Echarri,et al.  Modifying Choroidal Neovascularization Development with a Nutritional Supplement in Mice , 2015, Nutrients.

[29]  A. Aiuti,et al.  Clinical applications of gene therapy for primary immunodeficiencies. , 2015, Human gene therapy.

[30]  Kristian Vlahovicek,et al.  Genomation: a Toolkit to Summarize, Annotate and Visualize Genomic Intervals , 2015, Bioinform..

[31]  J. Roider,et al.  Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis , 2014, British Journal of Ophthalmology.

[32]  Anne Louise Askou,et al.  Development of gene therapy for treatment of age‐related macular degeneration , 2014, Acta ophthalmologica.

[33]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[34]  M. Mandai,et al.  Characterization of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Sheets Aiming for Clinical Application , 2014, Stem cell reports.

[35]  G. Lutty,et al.  VEGF Receptor Blockade Markedly Reduces Retinal Microglia/Macrophage Infiltration into Laser-Induced CNV , 2013, PloS one.

[36]  P. Coffey,et al.  Development of human embryonic stem cell therapies for age-related macular degeneration , 2013, Trends in Neurosciences.

[37]  A. García-Layana,et al.  Transforming Growth Factor-Beta Inhibition Reduces Progression of Early Choroidal Neovascularization Lesions in Rats: P17 and P144 Peptides , 2013, PloS one.

[38]  N. Ershov,et al.  Rat retinal transcriptome: Effects of aging and AMD-like retinopathy , 2013, Cell cycle.

[39]  A. García-Layana,et al.  Azithromycin reduces inflammation in a rat model of acute conjunctivitis , 2013, Molecular vision.

[40]  F. Mavilio,et al.  Mechanisms of retroviral integration and mutagenesis. , 2013, Human gene therapy.

[41]  N. Scott,et al.  RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2013, Retina.

[42]  Z. Izsvák,et al.  Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  J. Jonas,et al.  Cytokine concentration in aqueous humour of eyes with exudative age‐related macular degeneration , 2012, Acta ophthalmologica.

[44]  Z. Izsvák,et al.  Sleeping Beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. , 2012, Investigative ophthalmology & visual science.

[45]  Usha Chakravarthy,et al.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.

[46]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[47]  Kevin A. T. Silverstein,et al.  TAPDANCE: An automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data , 2012, BMC Bioinformatics.

[48]  Z. Izsvák,et al.  Retargeting transposon insertions by the adeno-associated virus Rep protein , 2012, Nucleic acids research.

[49]  Michel Sadelain,et al.  Safe harbours for the integration of new DNA in the human genome , 2011, Nature Reviews Cancer.

[50]  A. García-Layana,et al.  Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides. , 2011, Investigative ophthalmology & visual science.

[51]  Z. Izsvák,et al.  Nonviral gene delivery with the sleeping beauty transposon system. , 2011, Human gene therapy.

[52]  R. Khokha,et al.  Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3. , 2011, Investigative ophthalmology & visual science.

[53]  Alessandro Guffanti,et al.  High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. , 2010, Blood.

[54]  S. Ekker,et al.  Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  R. K. Murthy,et al.  Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells , 2010, Molecular vision.

[56]  W. Drexler,et al.  Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study , 2010, British Journal of Ophthalmology.

[57]  Frederik De Smet,et al.  Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way , 2009, Nature Reviews Clinical Oncology.

[58]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[59]  P. Walter,et al.  Preservation of photoreceptors in dystrophic RCS rats following allo- and xenotransplantation of IPE cells , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[60]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[61]  P. Debré,et al.  CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. , 2007, The Journal of clinical investigation.

[62]  P. Wiedemann,et al.  Positive feedback regulation between MMP-9 and VEGF in human RPE cells. , 2007, Investigative ophthalmology & visual science.

[63]  J. Kowalak,et al.  Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. , 2007, Investigative ophthalmology & visual science.

[64]  G. Gao,et al.  Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. , 2006, Journal of molecular endocrinology.

[65]  E. T. Ek,et al.  Pigment epithelium-derived factor: a multimodal tumor inhibitor , 2006, Molecular Cancer Therapeutics.

[66]  K. Bartz-Schmidt,et al.  Iris pigment epithelial translocation in the treatment of exudative macular degeneration: a 3-year follow-up. , 2006, Archives of ophthalmology.

[67]  R. Lutz,et al.  Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. , 2005, Investigative ophthalmology & visual science.

[68]  Lois E. H. Smith,et al.  Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. , 2005, Investigative ophthalmology & visual science.

[69]  P. Campochiaro,et al.  Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. , 2005, Human gene therapy.

[70]  Zoltán Ivics,et al.  Sleeping beauty transposition: biology and applications for molecular therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  L. Montuenga,et al.  Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. , 2004, Experimental eye research.

[72]  P. McGuire,et al.  Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition , 2003, Progress in Retinal and Eye Research.

[73]  C. Barnstable,et al.  PEDF: a multifaceted neurotrophic factor , 2003, Nature Reviews Neuroscience.

[74]  G. Thakker,et al.  Analysis of VEGF-responsive Genes Involved in the activation of endothelial cells , 2003, Molecular Cancer.

[75]  Daniel F Voytas,et al.  Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. , 2002, Journal of molecular biology.

[76]  R. Lund,et al.  Preservation of visual responsiveness in the superior colliculus of RCS rats after retinal pigment epithelium cell transplantation , 2002, Neuroscience.

[77]  S. Kochanek,et al.  Autologous transplantation of genetically modified iris pigment epithelial cells: A promising concept for the treatment of age-related macular degeneration and other disorders of the eye , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Campochiaro,et al.  AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.

[79]  R. Hilgers,et al.  Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: a pilot study. , 2002, American journal of ophthalmology.

[80]  P. Campochiaro,et al.  Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). , 2001, Human gene therapy.

[81]  Ronald Klein,et al.  The prevalence of age-related macular degeneration and associated risk factors. , 2001, Archives of ophthalmology.

[82]  P Esser,et al.  Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. , 2000, Archives of ophthalmology.

[83]  B. Kirchhof,et al.  Iris pigment epithelial cell translocation in exudative age-related macular degeneration , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[84]  M. Kay,et al.  Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system , 2000, Nature Genetics.

[85]  K. Heimann,et al.  The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells. , 1998, Experimental eye research.

[86]  J. P. Schwartz,et al.  Pigment epithelium‐derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes , 1997, Journal of neuroscience research.

[87]  P. Gouras,et al.  Tolerance of human fetal retinal pigment epithelium xenografts in monkey retina , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.

[88]  R. Klein,et al.  Prevalence of age-related maculopathy. The Beaver Dam Eye Study. , 1992, Ophthalmology.

[89]  J. Tombran-Tink,et al.  PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. , 1991, Experimental eye research.

[90]  T. Okada.  Recent progress in studies of the transdifferentiation of eye tissue in vitro. , 1983, Cell differentiation.

[91]  K. Yasuda,et al.  A demonstration of a switch of cell type in human fetal eye tissues in vitro: pigmented cells of the iris or the retina can transdifferentiate into lens. , 1978, Experimental eye research.

[92]  H. Schatz.  Sloughing of skin following fluorescein extravasation. , 1978, Annals of ophthalmology.

[93]  H. Einsele,et al.  Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors , 2017, Leukemia.

[94]  Z. Izsvák,et al.  Sleeping Beauty Transposition , 2015, Microbiology spectrum.

[95]  Sonia Mehta,et al.  Age-Related Macular Degeneration. , 2015, Primary care.

[96]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[97]  F. Cogé,et al.  The role of the matrix metalloproteinases during in vitro vessel formation , 2004, Angiogenesis.

[98]  H. Grossniklaus,et al.  Choroidal neovascularization. , 2004, American journal of ophthalmology.

[99]  G. Thumann,et al.  Development and cellular functions of the iris pigment epithelium. , 2001, Survey of ophthalmology.

[100]  A. Reiner,et al.  Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.

[101]  K. Ohno-Matsui,et al.  SUBRETINAL BLEEDING WITHOUT CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA: A Sign of New Lacquer Crack Formation , 1996, Retina.

[102]  D. Ingber,et al.  Inhibition of angiogenesis. , 1992, Seminars in cancer biology.

[103]  T. Okada.  Cellular metaplasia or transdifferentiation as a model for retinal cell differentiation. , 1980, Current topics in developmental biology.